［1］SIEGEL RL,MILLER KD,WAGLE NS,et al.Cancer statistics,2023［J］.CA Cancer J Clin,2023,73:17-48.
［2］ZHENG RS，ZHANG SW，ZENG H，et al.Cancer incidence and mortality in China，2016［J］.Journal of the National Cancer Center，2022，2(1)：1-9.
［3］TARANTINO P，CURIGLIANO G，TOLANEY SM.Navigating the HER2-low paradigm in breast oncology：New standards，future horizons［J］.Cancer Discov，2022，12(9)：2026-2030.
［4］AGOSTINETTO E，REDITI M，FIMERELI D，et al.HER2-low breast cancer：Molecular characteristics and prognosis［J］.Cancers（Basel)，2021，13(11):2824.
［5］SCHETTINI F，CHIC N，BRASO-MARISTANY F，et al.Clinical，pathological，and PAM50 gene expression features of HER2-low breast cancer［J］.NPJ Breast Cancer，2021，7(1)：1.
［6］TARANTINO P，JIN Q，TAYOB N，et al.Prognostic and biologic significance of ERBB2-low expression in early-stage breast cancer［J］.JAMA Oncol，2022，8(8)：1177-1183.
［7］MIGLIETTA F，GRIGUOLO G，BOTTOSSO M，et al.Evolution of HER2-low expression from primary to recurrent breast cancer［J］.NPJ Breast Cancer，2021，7(1)：137.
［8］GAMPENRIEDER SP，RINNERTHALER G，TINCHON C，et al.Landscape of HER2-low metastatic breast cancer（MBC)：results from the Austrian AGMT_MBC-Registry［J］.Breast Cancer Res，2021，23(1)：112.
［9］HORISAWA N，ADACHI Y，TAKATSUKA D，et al.The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status［J］.Breast Cancer，2022，29(2)：234-241.
［10］JACOT W，MARAN-GONZALEZ A，MASSOL O，et al.Prognostic value of HER2-low expression in non-metastatic triple-negative breast cancer and correlation with other biomarkers［J］.Cancers（Basel)，2021，13(23):6059.
［11］WON HS，AHN J，KIM Y，et al.Clinical significance of HER2-low expression in early breast cancer：A nationwide study from the Korean Breast Cancer Society［J］.Breast Cancer Res，2022，24(1)：22.
［12］ERGUN Y，UCAR G，AKAGUNDUZ B.Comparison of HER2-zero and HER2-low in terms of clinicopathological factors and survival in early-stage breast cancer：A systematic review and Meta-analysis［J］.Cancer Treat Rev，2023，115：102538.
［13］BAEZ-NAVARRO X，VAN BOCKSTAL MR，ANDRINOPOULOU ER，et al.HER2-low breast cancer：Incidence，clinicopathologic features，and survival outcomes from real-world data of a large nationwide cohort［J］.Mod Pathol，2023，36(4)：100087.
［14］DEHGHANI M，KESHAVARZ P，TALEI A，et al.The effects of low HER2/neu expression on the clinicopathological characteristics of triple-negative breast cancer patients［J］.Asian Pac J Cancer Prev，2020，21(10)：3027-3032.
［15］HEIN A，HARTKOPF AD，EMONS J，et al.Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status［J］.Eur J Cancer，2021，155：1-12.
［16］ZHANG G，REN C，LI C，et al.Distinct clinical and somatic mutational features of breast tumors with high-，low-，or non-expressing human epidermal growth factor receptor 2 status［J］.BMC Med，2022，20(1)：142.
［17］DENKERT C，SEITHER F，SCHNEEWEISS A，et al.Clinical and molecular characteristics of HER2-low-positive breast cancer：Pooled analysis of individual patient data from four prospective，neoadjuvant clinical trials［J］.The Lancet Oncology，2021，22(8)：1151-1161.
［18］KANG S，LEE SH，LEE HJ，et al.Pathological complete response，long-term outcomes，and recurrence patterns in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy［J］.Eur J Cancer，2022，176：30-40.
［19］YANG C，ZHANG X，CHEN Y，et al.Survival differences between HER2-0 and HER2-low-expressing breast cancer-a Meta-analysis of early breast cancer patients［J］.Crit Rev Oncol Hematol，2023，185：103962.
［20］ONSUM MD，GERETTI E，PARAGAS V，et al.Single-cell quantitative HER2 measurement identifies heterogeneity and distinct subgroups within traditionally defined HER2-positive patients［J］.Am J Pathol，2013，183(5)：1446-1460.
［21］DRAGO JZ，MODI S，CHANDARLAPATY S.Unlocking the potential of antibody-drug conjugates for cancer therapy［J］.Nat Rev Clin Oncol，2021，18(6)：327-344.
［22］LI JY，PERRY SR，MUNIZ-MEDINA V，et al.A biparatopic HER2-targeting antibody-drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-targeted therapy［J］.Cancer Cell，2019，35(6)：948-949.
［23］TRAIL PA，DUBOWCHIK GM，LOWINGER TB.Antibody drug conjugates for treatment of breast cancer：Novel targets and diverse approaches in ADC design［J］.Pharmacol Ther，2018，181：126-142.
［24］FERRARO E，DRAGO JZ，MODI S.Implementing antibody-drug conjugates（ADCs) in HER2-positive breast cancer：State of the art and future directions［J］.Breast Cancer Res，2021，23(1)：84.
［25］BARGH JD，ISIDRO-LLOBET A，PARKER JS，et al.Cleavable linkers in antibody-drug conjugates［J］.Chem Soc Rev，2019，48(16)：4361-4374.
［26］DE SANCTIS R，JACOBS F，BENVENUTI C，et al.From seaside to bedside：Current evidence and future perspectives in the treatment of breast cancer using marine compounds［J］.Front Pharmacol，2022，13：909566.
［27］MODI S，PARK H，MURTHY RK，et al.Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer：Results from a phase Ⅰb study［J］.J Clin Oncol，2020，38(17)：1887-1896.
［28］MODI S，JACOT W，YAMASHITA T，et al.Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer［J］.New England Journal of Medicine，2022，387(1)：9-20.
［29］PEREZ-GARCIA JM，VAZ BATISTA M，CORTEZ P，et al.Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer：The DEBBRAH trial［J］.Neuro Oncol，2023，25(1)：157-166.
［30］SCHMID P,NUNES AT,DRY H,et al.BEGONIA:Phase Ⅰb/Ⅱ,open-label,platform study of the safety and efficacy of durvalumab(D)±paclitaxel(P) with novel oncology therapies for first-line metastatic triple-negative breast cancer(mTNBC):Addition of arm 7,D+datopotamab deruxtecan (Dato-DXd;DS-1062)［J］.Journal of Clinical Oncology,2021,39(15_suppl):TPS1105.
［31］BANERJI U，VAN HERPEN CML，SAURA C，et al.Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer：A phase Ⅰ dose-escalation and dose-expansion study［J］.The Lancet Oncology，2019，20(8)：1124-1135.
［32］MANICH C，O'SHAUGHNESSY J，AFTIMOS PG，et al.LBA15 primary outcome of the phase Ⅲ SYD985.002/TULIP trial comparing［vic-］trastuzumab duocarmazine to physician's choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer［J］.Annals of Oncology，2021，32：S1288.
［33］DEEKS ED.Disitamab vedotin：First approval［J］.Drugs，2021，81(16)：1929-1935.
［34］WANG J，LIU Y，ZHANG Q，et al.RC48-ADC，a HER2-targeting antibody-drug conjugate，in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer：A pooled analysis of two studies［J］.Journal of Clinical Oncology，2021，39(15_suppl)：1022.
［35］ZHANG J,LIU R,GAO S,et al.Phase Ⅰ study of A166,an antibody-drug conjugate in advanced HER2-expressing solid tumours［J］.NPJ Breast Cancer,2023,9(1):28.
［36］LI H，ZHANG X，XU Z，et al.Preclinical evaluation of MRG002，a novel HER2-targeting antibody-drug conjugate with potent antitumor activity against HER2-positive solid tumors［J］.Antib Ther，2021，4(3)：175-184.
［37］YU J，FANG T，YUN C，et al.Antibody-drug conjugates targeting the human epidermal growth factor receptor family in cancers［J］.Front Mol Biosci，2022，9：847835.
［38］JIANG Z,SUN T,WANG X,et al.A multiple center,open-label,single-arm,phase Ⅱ clinical trial of MRG002,an HER2-targeted antibody-drug conjugate,in patients with HER2-low expressing advanced or metastatic breast cancer［J］.Journal of Clinical Oncology,2022,40(16_suppl):1102.
［39］LU J，BUDD GT，FRENTZAS S，et al.250TiP HER2-positive and HER2-low breast cancer patients in the ACE-Pan tumor-01 study：Phase I study evaluating ARX788 as monotherapy in advanced solid tumors with HER2 expression or mutation［J］.Annals of Oncology，2022，33：S223.
［40］SKIDMORE L，SAKAMURI S，KNUDSEN NA，et al.ARX788，a site-specific anti-HER2 antibody-drug conjugate，demonstrates potent and selective activity in HER2-low and T-DM1-resistant breast and gastric cancers［J］.Mol Cancer Ther，2020，19(9)：1833-1843.
［41］HAMBLETT K，HAMMOND P，BARNSCHER S，et al.Abstract 3914：ZW49，a HER2-targeted biparatopic antibody-drug conjugate for the treatment of HER2-expressing cancers［J］.Cancer Research，2018，78(13 supplement)：3914.
［42］HAMBLETT K，BARNSCHER S，DAVIES R，et al.Abstract P6-17-13：ZW49，a HER2 targeted biparatopic antibody drug conjugate for the treatment of HER2 expressing cancers［J］.Cancer Research，2019，79(4_Supplement)：P6-17-13.
［43］JHAVERI K，HAN H，DOTAN E，et al.460MO preliminary results from a phase Ⅰ study using the bispecific，human epidermal growth factor 2（HER2)-targeting antibody-drug conjugate（ADC) zanidatamab zovodotin（ZW49) in solid cancers［J］.Annals of Oncology，2022，33：S749-S750.
［44］HAFEEZ U，PARAKH S，GAN HK，et al.Antibody-drug conjugates for cancer therapy［J］.Molecules，2020，25(20):4764.